You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Medtronic
McKesson

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

QUILLICHEW ER Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Quillichew Er patents expire, and when can generic versions of Quillichew Er launch?

Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-eight patent family members in fourteen countries.

The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Drug patent expirations by year for QUILLICHEW ER
Drug Prices for QUILLICHEW ER

See drug prices for QUILLICHEW ER

Recent Clinical Trials for QUILLICHEW ER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 4

See all QUILLICHEW ER clinical trials

Pharmacology for QUILLICHEW ER
Paragraph IV (Patent) Challenges for QUILLICHEW ER
Tradename Dosage Ingredient NDA Submissiondate
QUILLICHEW ER TABLET, EXTENDED RELEASE, CHEWABLE;ORAL methylphenidate hydrochloride 207960 2016-04-25

US Patents and Regulatory Information for QUILLICHEW ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Nextwave Pharms QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.